SHR-1819 for Eczema: Interpreting a 157-Patient IL-4 Receptor Trial

Dr. Arsy Editorial Team · November 9, 2026

SHR-1819 is an investigational antibody targeting the interleukin-4 receptor alpha pathway. A 157-patient phase 2 trial reported higher week-16 response rates across three dosing regimens than placebo. These findings support further study, but they do not establish approval, long-term safety, or superiority to established IL-4/IL-13 pathway therapies.^[3]

Trial design and primary endpoint

Adults with EASI scores of at least 16, IGA scores of at least 3, and at least 10% affected body surface area were randomized to 300 mg every two weeks, 600 mg every two weeks, 600 mg every four weeks, or placebo. All participants were instructed to use moisturizer before and throughout the trial. The primary outcome was EASI-75 at week 16.

Response rates need their denominator and context

EASI-75 was achieved by 69.2%, 75.0%, and 85.4% of the three SHR-1819 groups versus 37.8% with placebo. IGA and peak-itch outcomes also numerically favored active treatment. Treatment-related adverse events were reported in 45.8% across SHR-1819 groups and 40.5% with placebo; reported events included injection-site reactions, increased bilirubin and conjunctivitis.^[3]

What the trial does not show

There was no direct comparison with dupilumab, tralokinumab, lebrikizumab, or another systemic therapy. Results from those separate trials cannot be placed into a simple league table because entry criteria, background therapy, statistical plans and populations differ. A phase 2 study also offers limited exposure for detecting rare or delayed adverse outcomes.^{[12][18][19][20]}

Why biomarker changes are supportive, not decisive

The study reported reductions in several type 2 inflammatory biomarkers. Biomarkers can strengthen biological plausibility, but a patient-centered decision depends on symptoms, disease control, quality of life, safety, monitoring, cost and access. A laboratory change should never substitute for a clinical outcome.

People considering systemic eczema treatment should review approved choices, contraindications and monitoring with a clinician. SHR-1819 remains an investigational option represented by this particular trial, not a recommendation for self-directed use.

Where Dr. Arsy #003 fits

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not tested in the study reviewed here and should not be described as producing the study treatment’s effects. It does not diagnose, treat, cure or prevent eczema.

Continue reading

• QY201 for Eczema: What a 200-Adult Phase 2 Trial Found
• EP262 for Atopic Dermatitis: A Well-Tolerated Phase 2 Study Without Clinical Benefit
• Temtokibart and Eczema: What Targeting IL-22RA1 Showed in Phase 2a
• Herbal Baths for Eczema: Reading a 66-Patient Add-On Trial Carefully
• Related Dr. Arsy eczema research guide
• Related Dr. Arsy eczema research guide

Research and clinical references

1. QY201 phase 2 dose-finding trial in adult atopic dermatitis.
2. EP262 MRGPRX2-antagonist EASE study.
3. SHR-1819 anti-IL-4Rα phase 2 study.
4. Temtokibart IL-22RA1 phase 2a study.
5. Herbal-bath randomized trial for mild-to-moderate atopic dermatitis.
6. ICP-332 phase 2 randomized clinical trial.
7. Pumecitinib 3% gel phase 2b trial.
8. Rezpegaldesleukin REZOLVE-AD phase 2b study.
9. Ivarmacitinib phase 3 randomized clinical trial.
10. Ivarmacitinib outcomes through week 52.
11. Model-based meta-analysis of randomized atopic dermatitis treatments.
12. Meta-analysis of IL-4Rα inhibitors for atopic dermatitis.
13. Antihistamines for eczema: systematic review and network meta-analysis.
14. American Academy of Dermatology adult systemic and phototherapy guideline.
15. American Academy of Dermatology adult topical-therapy guideline.
16. American Academy of Dermatology pediatric management guideline.
17. AAAAI/ACAAI atopic dermatitis clinical guideline.
18. Lebrikizumab phase 3 ADvocate trials.
19. Tralokinumab ECZTRA 1 and ECZTRA 2 trials.
20. Dupilumab phase 3 SOLO 1 and SOLO 2 trials.
21. Upadacitinib phase 3 Measure Up 1 and 2 trials.
22. Abrocitinib phase 3 JADE MONO-1 trial.
23. Roflumilast cream INTEGUMENT trials.
24. Tapinarof cream ADORING trials.

Educational information only; not a diagnosis or personalized medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.